Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...
Late last week, J&J said that the new approach for Xarelto and Stelara – both drugs subject to the first round of Medicare negotiations under the Inflation Reduction Act (IRA) with prices ...
Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results